AGL · Agilon Health, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.42B | - | $1.44B | $1.39B | $1.53B | - | $1.45B | $1.48B | $1.60B | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $54.23M | - | $56.20M | $56.28M | $65.96M | - | $63.12M | $69.61M | $76.42M | - |
| Total Operating Expenses | $1.42B | - | $1.57B | $1.51B | $1.55B | - | $1.58B | $1.53B | $1.61B | - |
| D&A | $6.79M | - | $7.43M | $7.32M | $6.88M | - | $6.22M | $5.91M | $5.84M | - |
| Operating Income | $4.00M | - | ($131.27M) | ($116.03M) | ($22.11M) | - | ($133.51M) | ($43.34M) | ($7.18M) | - |
| Interest Expense | $1.81M | - | $1.84M | $1.57M | $1.28M | - | $1.62M | $1.70M | $1.28M | - |
| Income Tax | $28.0K | - | ($331.0K) | $62.0K | $196.0K | - | ($590.0K) | $417.0K | ($133.0K) | - |
| Net Income | $48.92M | - | ($110.21M) | ($104.37M) | $12.11M | - | ($117.61M) | ($30.68M) | ($6.06M) | - |
| EPS - Basic | $0.73 | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | $0.73 | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $139.99M | $173.71M | $171.68M | $171.42M | $136.94M | $188.23M | $148.16M | $109.49M | $111.71M | $107.57M |
| Accounts Receivable | $899.75M | $673.79M | $947.16M | $1.05B | $1.24B | $1.02B | $1.37B | $1.44B | $1.57B | $942.46M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $1.32B | $1.10B | $1.34B | $1.45B | $1.65B | $1.46B | $1.81B | $1.88B | $2.04B | $1.48B |
| Total Assets | $1.50B | $1.27B | $1.60B | $1.71B | $1.93B | $1.73B | $2.09B | $2.16B | $2.32B | $1.74B |
| Current Liabilities | $1.27B | $1.08B | $1.24B | $1.25B | $1.37B | $1.15B | $1.41B | $1.39B | $1.53B | $977.16M |
| Long-term Debt | $15.28M | $15.75M | $0 | $0 | $0 | $34.90M | $34.88M | $27.36M | $29.83M | $32.31M |
| Total Liabilities | $1.32B | $1.14B | $1.29B | $1.30B | $1.43B | $1.26B | $1.52B | $1.49B | $1.63B | $1.08B |
| Stockholders' Equity | $181.43M | $126.73M | $306.08M | $408.93M | $500.25M | $470.95M | $574.87M | $676.63M | $689.27M | $661.84M |
| Retained Earnings | ($1.93B) | ($1.98B) | ($1.79B) | ($1.68B) | ($1.57B) | ($1.59B) | ($1.48B) | ($1.36B) | ($1.33B) | ($1.33B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $23.73M | - | - | - | ($31.99M) | - | - | - | ($47.78M) | - |
| Investing Cash Flow | $19.27M | - | - | - | ($23.09M) | - | - | - | $51.44M | - |
| Financing Cash Flow | ($5.15M) | - | - | - | ($161.0K) | - | - | - | $559.0K | - |
| CapEx | $3.10M | - | - | - | $3.85M | - | - | - | $3.14M | - |
| Free Cash Flow | $20.63M | - | - | - | ($35.84M) | - | - | - | ($50.91M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 0.3% | - | -9.1% | -8.3% | -1.4% | - | -9.2% | -2.9% | -0.4% | - |
| EBITDA margin | 0.8% | - | -8.6% | -7.8% | -1.0% | - | -8.8% | -2.5% | -0.1% | - |
| Net margin | 3.4% | - | -7.7% | -7.5% | 0.8% | - | -8.1% | -2.1% | -0.4% | - |
| Free cash flow margin | 1.5% | - | - | - | -2.3% | - | - | - | -3.2% | - |
| FCF / Net income | 0.42 | - | - | - | -2.96 | - | - | - | 8.40 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 3.8% | - | 3.9% | 4.0% | 4.3% | - | 4.4% | 4.7% | 4.8% | - |
| Effective tax rate | 0.1% | - | - | - | 1.6% | - | - | - | - | - |
| Return on assets | 3.3% | - | -6.9% | -6.1% | 0.6% | - | -5.6% | -1.4% | -0.3% | - |
| Return on equity | 27.0% | - | -36.0% | -25.5% | 2.4% | - | -20.5% | -4.5% | -0.9% | - |
| Return on invested capital | 2.0% | - | -33.9% | -22.4% | -4.3% | - | -17.3% | -4.9% | -0.8% | - |
| Liquidity | ||||||||||
| Current ratio | 1.04 | 1.02 | 1.08 | 1.16 | 1.20 | 1.27 | 1.29 | 1.36 | 1.33 | 1.51 |
| Quick ratio | 1.04 | 1.02 | 1.08 | 1.16 | 1.20 | 1.27 | 1.29 | 1.36 | 1.33 | 1.51 |
| Cash ratio | 0.11 | 0.16 | 0.14 | 0.14 | 0.10 | 0.16 | 0.11 | 0.08 | 0.07 | 0.11 |
| Leverage | ||||||||||
| Debt / Equity | 0.08 | 0.12 | 0.00 | 0.00 | 0.00 | 0.07 | 0.06 | 0.04 | 0.04 | 0.05 |
| Debt / Assets | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 |
| Debt / EBITDA | 1.42 | - | - | - | - | - | - | - | - | - |
| Interest coverage | 2.2x | - | -71.4x | -73.8x | -17.2x | - | -82.3x | -25.5x | -5.6x | - |
| Equity multiplier | 8.29 | 10.03 | 5.22 | 4.19 | 3.86 | 3.68 | 3.64 | 3.20 | 3.36 | 2.63 |
| Liabilities / Assets | 0.88 | 0.90 | 0.81 | 0.76 | 0.74 | 0.73 | 0.73 | 0.69 | 0.70 | 0.62 |
| Efficiency | ||||||||||
| Asset turnover | 0.94 | - | 0.90 | 0.81 | 0.79 | - | 0.69 | 0.69 | 0.69 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 231d | - | 241d | 274d | 295d | - | 344d | 354d | 357d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 10.8x | - | - | - | - | - | - | - | - | - |
| P / B | 0.7x | - | 34.9x | 58.2x | 89.4x | - | 70.3x | 99.4x | 91.5x | - |
| P / S | 0.1x | - | 7.4x | 17.1x | 29.2x | - | 27.9x | 45.3x | 39.3x | - |
| EV / EBITDA | 0.7x | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -7.3% | - | -1.1% | -5.9% | -4.5% | - | 19.4% | 29.0% | 41.2% | - |
| Revenue CAGR (3y) | 7.7% | - | 27.4% | 27.7% | 32.9% | - | 66.8% | 43.8% | 76.6% | - |
| Revenue CAGR (5y) | 37.3% | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | 1.7% | -167.7% | -208.0% | - | -172.6% | -45.3% | - | - |
| Net income growth (YoY) | 303.9% | - | 6.3% | -240.2% | - | - | -274.1% | -83.2% | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 29.6% | - | - | - | 21.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -63.7% | -73.1% | -46.8% | -39.6% | -27.4% | -28.8% | -34.1% | -23.1% | -36.3% | -36.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$5.93B totalMedical Services$5.92B · 99.8%
Other Operating$11.23M · 0.2%
Peer comparison
Same SIC group: Services-Misc Health & Allied Services, NEC
Comparing agilon health against the 5 most active filers in the same SIC group.